NCT05186012 - APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2026

Conditions

NHL, Adult

Interventions

DRUG

APG-1252

APG-1252 administered via intravenous infusion for 30 minutes weekly (Day 1, 8, 15, 22).Every 28 days as a cycle.

DRUG

Chidamide

Chidamide 30mg orally BIW. Every 28 days as a cycle.

Trial Locations (4)

NOT_YET_RECRUITING

Henan Provincial Oncology Hospital, Zhengzhou

NOT_YET_RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

NOT_YET_RECRUITING

Jiangsu Province Hospital, Nanyang

RECRUITING

Shanghai Jiao Tong University school of medicine Ruijin Hospital, Shanghai